Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Incyte (INCY) Tops Q1 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus
April 30, 2019 7:12 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of $0.62, $0.22 better than the analyst estimate of $0.40. Revenue for the quarter came in at $498 million versus the consensus estimate of $489.03 million.
Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019Jakafi® (ruxolitinib) revenues of $376 million in Q1 2019 (+20%... More